Good evening :)
$
₹
Pacific Biosciences of California

Pacific Biosciences of California

PACB

NASDAQ
Asset Logo

Pacific Biosciences of California

PACB

NASDAQ
$1.392.57% (+0.03)
$
₹
$1.392.57% (+0.03)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Medical Devices

Small Cap

With a market cap of $425.8M the stock is ranked 3488

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

170.66
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.42
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

-0.17
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-82.49%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 14 analysts' reports

Buy
6 analysts
Hold
8 analysts
Sell
0 analyst

Analysts expect a +58.61% price upside over the next year

Current Price$1.39
Target Price$2.15

Company Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Peers

Peers

Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
35.08
35.08
1Y Return
38.68%
38.68%
Buy Reco %
80.64
80.64
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
30.86
30.86
1Y Return
24.1%
24.1%
Buy Reco %
82.35
82.35
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
33.09
33.09
1Y Return
43.68%
43.68%
Buy Reco %
69.56
69.56
Waters Corporation
WAT
Waters Corporation
P/E Ratio
107.05
107.05
1Y Return
40.14%
40.14%
Buy Reco %
31.81
31.81
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
44.62
44.62
1Y Return
135.31%
135.31%
Buy Reco %
55.00
55.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Pacific Biosciences of California -170.66-0.17
Thermo Fisher Scientific Inc35.084.571.94
Agilent Technologies Inc30.865.991.29

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

38.4
-38
44.6
-40.3
37.1
-8.2
39
-44.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue38.8136.0139.9639.2237.1539.7638.4444.6437.1739
Net Income-78.17-173.31-60.722.37-426.07-41.93-38-40.37-8.27-44.74
Net Profit Margin-201.43%-481.26%-151.93%6.04%-1146.81%-105.44%-98.85%-90.42%-22.25%-114.69%
See CostsAll values in $ Million

Frequently asked questions

  1. Pacific Biosciences of California (PACB) share price today is $1.39 as of September 22, 2026 at 7:16 PM IST. The stock touched a day high of $1.39 and a day low of $1.35.

  2. Pacific Biosciences of California stock trades on NASDAQ under the ticker symbol PACB.

  3. Pacific Biosciences of California's market capitalization is $425.83M as of September 22, 2026 at 7:16 PM IST.

  4. Pacific Biosciences of California's price-to-earnings (P/E) ratio is N/A as of September 22, 2026.

  5. Pacific Biosciences of California's price-to-book (P/B) ratio is 170.66 as of September 22, 2026.

  6. Yes, You can buy Pacific Biosciences of California shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Pacific Biosciences of California shares in three steps: 1. Search Pacific Biosciences of California on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Pacific Biosciences of California trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Pacific Biosciences of California (PACB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 7.1684 shares at the current price of $1.39.

Loading...